Share on StockTwits

Infinity Pharmaceuticals (NASDAQ: INFI) received a number of price target changes and ratings updates during the last week:

  • Infinity Pharmaceuticals had its price target lowered by analysts at Nomura from $17.00 to $12.00.
  • Infinity Pharmaceuticals had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $20.00 price target on the stock, down previously from $24.00.
  • Infinity Pharmaceuticals had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $20.00 price target on the stock, down previously from $25.00.
  • Infinity Pharmaceuticals was upgraded by analysts at Jefferies Group from a “hold” rating to a “buy” rating. They now have a $13.00 price target on the stock, down previously from $15.00.
  • Infinity Pharmaceuticals had its price target lowered by analysts at Wedbush from $10.00 to $9.00.

Shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) opened at 9.85 on Tuesday. Infinity Pharmaceuticals Inc. has a 52 week low of $8.40 and a 52 week high of $33.93. The stock’s 50-day moving average is $10.4 and its 200-day moving average is $12.79. The company’s market cap is $478.1 million.

Infinity Pharmaceuticals, Inc (NASDAQ:INFI) is a drug discovery and development company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.